Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to the Summary (03/30/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Langerhans Cell Histiocytosis (LCH)

Added Nelson et al. as reference 6.

Histopathologic, Immunologic, and Cytogenetic Characteristics of LCH

The Cytogenetic and Genomic Studies subsection was extensively revised.

Treatment of Recurrent, Refractory, or Progressive Childhood LCH

Added text to state that all patients developed grade 4 hematologic toxicity, and five of these patients had severe sepsis.

Added text to state that reduced-intensity conditioning provides no overall survival advantage over myeloablative conditioning before hematopoietic stem cell transplantation for LCH patients; however, the relapse rate after reduced-intensity conditioning was significantly higher than the relapse rate after myeloablative conditioning. Many of the reduced-intensity conditioning patients who relapsed were successfully re-treated with chemotherapy alone (cited Veys et al. as reference 27).

Treatment of Adult LCH

Added Grobost et al. as reference 2 and level of evidence 3iiiC.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Adult LCH

Next section >
About This PDQ Summary